These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 29771880)

  • 41. Comparison of the short-term effect of aflibercept and dexamethasone implant on serous retinal detachment in the treatment of naive diabetic macular edema.
    Bolukbasi S; Cakir A; Erden B; Karaca G
    Cutan Ocul Toxicol; 2019 Dec; 38(4):401-405. PubMed ID: 31438736
    [No Abstract]   [Full Text] [Related]  

  • 42. Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab.
    Konidaris V; Al-Hubeshy Z; Tsaousis KT; Gorgoli K; Banerjee S; Empeslidis T
    Int Ophthalmol; 2018 Feb; 38(1):207-213. PubMed ID: 28405787
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Real-life experience of ranibizumab for diabetic macular edema in Taiwan.
    Tsai MJ; Hsieh YT; Peng YJ
    Int Ophthalmol; 2019 Jul; 39(7):1511-1522. PubMed ID: 29926364
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
    Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S
    Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794
    [TBL] [Abstract][Full Text] [Related]  

  • 45. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
    Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
    Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relationship Between Visual Acuity and Retinal Thickness During Anti-Vascular Endothelial Growth Factor Therapy for Retinal Diseases.
    Ou WC; Brown DM; Payne JF; Wykoff CC
    Am J Ophthalmol; 2017 Aug; 180():8-17. PubMed ID: 28549848
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of aflibercept on persistent macular edema secondary to central retinal vein occlusion.
    Kaya F; Kocak I; Aydin A; Baybora H; Koc H; Karabela Y
    J Fr Ophtalmol; 2018 Nov; 41(9):809-813. PubMed ID: 30361176
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluating initial responses to brolucizumab in patients undergoing conventional anti-VEGF therapy for diabetic macular edema: a retrospective, single-center, observational study.
    Hirano T; Kumazaki A; Tomihara R; Ito S; Hoshiyama K; Murata T
    Sci Rep; 2023 Jul; 13(1):10901. PubMed ID: 37407660
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dexamethasone Intravitreal Implant for Chronic Diabetic Macular Edema Resistant to Intravitreal Bevacizumab Treatment.
    Totan Y; Güler E; Gürağaç FB
    Curr Eye Res; 2016; 41(1):107-13. PubMed ID: 25610946
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of intravitreal injection of ranibizumab on choroidal structure and blood flow in eyes with diabetic macular edema.
    Okamoto M; Yamashita M; Ogata N
    Graefes Arch Clin Exp Ophthalmol; 2018 May; 256(5):885-892. PubMed ID: 29492689
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study.
    Pearce I; Banerjee S; Burton BJ; Chakravarthy U; Downey L; Gale RP; Gibson J; Pagliarini S; Patel J; Sivaprasad S; Andrews C; Brittain C; Warburton J;
    Ophthalmology; 2015 Sep; 122(9):1811-9. PubMed ID: 26150052
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study.
    Xu Y; Rong A; Xu W; Niu Y; Wang Z
    BMC Ophthalmol; 2017 Aug; 17(1):158. PubMed ID: 28841827
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Progress of Diabetic Macular Edema after Loading Injection of Anti-Vascular Endothelial Growth Factor Agents in Real-World Cases.
    Enomoto H; Sugimoto M; Asami S; Kondo M
    Medicina (Kaunas); 2022 Sep; 58(10):. PubMed ID: 36295479
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [What can anti-VEGF therapy achieve in clinical routine? : Effectiveness of anti-VEGF therapy in patients with macular diseases in clinical routine on 1492 eyes in Austria].
    Wiesinger K; Reinelt P; Ennemoser A; Edelmayr M; Schönherr U
    Ophthalmologe; 2017 Jul; 114(7):639-645. PubMed ID: 27815675
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of intravitreal bevacizumab for macular edema following branch retinal vein occlusion stratified by baseline visual acuity.
    Kim M; Jeong S; Sagong M
    Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):691-697. PubMed ID: 27796671
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Practical Lessons from Protocol T for the Management of Diabetic Macular Edema.
    Mukkamala L; Bhagat N; Zarbin M
    Dev Ophthalmol; 2017; 60():109-124. PubMed ID: 28427070
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vision Outcomes Following Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice.
    Holekamp NM; Campbell J; Almony A; Ingraham H; Marks S; Chandwani H; Cole AL; Kiss S
    Am J Ophthalmol; 2018 Jul; 191():83-91. PubMed ID: 29684329
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema.
    Nepomuceno AB; Takaki E; Paes de Almeida FP; Peroni R; Cardillo JA; Siqueira RC; Scott IU; Messias A; Jorge R
    Am J Ophthalmol; 2013 Sep; 156(3):502-510.e2. PubMed ID: 23795985
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Anti-VEGF therapy for age-related macular degeneration].
    Fursova AZ; Chubar NV; Tarasov MS; Vasilyeva MA; Gusarevich OG
    Vestn Oftalmol; 2018; 134(6):59-67. PubMed ID: 30721202
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The macular function and structure in patients with diabetic macular edema before and after ranibizumab treatment.
    Nowacka B; Kirkiewicz M; Mozolewska-Piotrowska K; Lubiński W
    Doc Ophthalmol; 2016 Apr; 132(2):111-22. PubMed ID: 27000269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.